Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen

Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen. Blood. 2005; 106(11):601a.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.